Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.

C Franzius1, S Bielack, J Sciuk

  • 1Department of Nuclear Medicine, University Hospital, Münster, Germany. franziu@uni-muenster.de

Nuklearmedizin. Nuclear Medicine
|January 1, 2000
PubMed
Summary

High-activity Samarium-153-EDTMP therapy combined with other treatments significantly improved local control and reduced pain in a patient with unresectable osteosarcoma. This multimodal approach shows promise for advanced bone cancer cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021
Same author

No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021
Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here: Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tübingen, Germany.

Molecular imaging and biology·2015
Same author

[Adherence to Long-term Follow-up in Paediatric Oncology--Results of a Monocentric Analysis].

Klinische Padiatrie·2015
Same author

Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany.

Molecular imaging and biology·2015

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiotherapy

Background:

  • Osteosarcoma often has a poor prognosis, especially when unresectable, despite effective chemotherapy.
  • Multimodal therapy is crucial for improving outcomes in advanced osteosarcoma cases.
  • High-activity radiopharmaceuticals offer targeted treatment options for bone cancers.

Observation:

  • A 21-year-old female patient with unresectable pelvic osteosarcoma and pulmonary metastases received high-activity Samarium-153-EDTMP (Sm-153-EDTMP).
  • The treatment was part of a multimodal regimen including external radiotherapy, continued polychemotherapy, and stem cell support.
  • The patient experienced complete pain relief within 48 hours of Sm-153-EDTMP administration.

Findings:

  • Bone scintigraphy and PET scans showed decreased tracer uptake and reduced glucose metabolism in primary tumors and metastases.

Related Experiment Videos

  • Thoracic CT confirmed a reduction in the size of pulmonary metastases.
  • The multimodal therapy demonstrated a positive response in local tumor control and metastatic disease.

    • Implications:

    • This case highlights the potential feasibility and efficacy of combining high-activity Sm-153-EDTMP therapy with conventional treatments for unresectable osteosarcomas.
    • Further evaluation is warranted to establish this multimodal approach as a standard treatment option.
    • Targeted radionuclide therapy combined with other modalities may improve outcomes for patients with advanced bone cancers.